.png){kind=icon}
.png){kind=icon}
Return
Can we cure primary biliary cholangitis?
.png){kind=icon}
OA
AI
P
G
M
DOI：10.1016/j.coi.2026.102786.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Primary biliary cholangitis (PBC) is a chronic immune-mediated liver disease characterized by progressive destruction of the intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventual cirrhosis. Despite advances in understanding disease pathogenesis, treatment pathways are focused on maintenance rather than cure. Moreover, the lion’s share of therapeutic advances have been in the bile acid space, with currently available agents geared toward attenuating (rather than reversing) liver disease progression.
Keywords:
primary biliary cholangitis
immune-mediated liver disease
bile duct destruction
cholestasis
liver fibrosis
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
5.8
Papers:
3.4K
Citations:
9.5K
View more organizations